twistbioscience.com

Twist Bioscience (NASDAQ: TWST) is the category-leading silicon-array gene synthesis vendor with an estimated 26.2% share of the 2026 global gene synthesis market. The April 2026 monitoring period is dominated by three structural events: (1) the GA launch of Twist's enzymatic-error-correction platform, achieving 1:18,400 error rates at 2.4 kb and reframing the long-read fidelity discussion against phosphoramidite legacy; (2) Q2 FY26 earnings raising full-year guidance to $410–425M with SynBio and NGS Tools both growing >40% YoY; (3) the disclosure of a strategic GMP capacity expansion in Wilsonville, Oregon — adding ~620 kbp/day of GMP-grade capacity by Q4 2027 and addressing the AAV payload demand pull. The dominant competitive thread is share redistribution: Ansa Biotechnologies and DNA Script's enzymatic platforms reach $0.05/base GMP threshold in 2027, compressing Twist's research-grade ASP by an estimated 38% over the forecast horizon while its GMP-grade ASP rises 12%. Three sell-side analysts upgraded to Buy in April; one downgraded on phosphoramidite supply risk. Customer signal is strongly positive across CDMO and pharma segments, with Moderna disclosing a multi-year GMP supply agreement in Q1 and three top-twenty pharma customers (undisclosed) committing 2027 capacity in advance. Watch items for the next 90 days: (i) BIS export-control posture on APAC research-grade orders; (ii) Q3 FY26 cash burn against the Wilsonville build; (iii) competitive response to the enzymatic-EC announcement from IDT/Danaher.